SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
NKTR Drug delivery Company
An SI Board Since September 2005
Posts SubjectMarks Bans Symbol
507 31 0 NKTR
Emcee:  david nordic Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
432The tell is the quality of the English.DewDiligence_on_SI110/4/2018
431Is there a specific tell or just general tone from reading it?ghmm-10/4/2018
430Though its certainly lacking management has given an explanation (the data need ghmm-10/4/2018
429After examining the "rebuttal" text more closely, I'm certain thatDewDiligence_on_SI-10/4/2018
428<If not I still think they shouldn't get involved in a public debate...&gMiljenko Zuanic-10/4/2018
427I hadn't noticed that the rebuttal is supposedly from NKTR. If in fact, it ghmm110/4/2018
426There was a quote from Jennifer Ruddock (their IR contact) with a general there ghmm-10/4/2018
425Life is too short to get involved in this kind of debate, LOL.DewDiligence_on_SI-10/4/2018
424seekingalpha.com Interesting dialogue between beej (new/fresh to SA) and PlainvMiljenko Zuanic-10/4/2018
423IF that is indeed their rebuttal, Yes. IF not, make their own and explain to inMiljenko Zuanic-10/4/2018
422NKTR should disclose its rebuttal in an 8-K filing.DewDiligence_on_SI-10/4/2018
421<The e-mail continues: Modified T Reg Increase in the Peripheral Blood and NMiljenko Zuanic-10/4/2018
420One think that concern me very much about NK-214 is from P1 presentation:..10-foMiljenko Zuanic-10/2/2018
419Main explanation of the "short" report is absence of the effect-LymphoMiljenko Zuanic110/1/2018
418 O4 Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untMiljenko Zuanic-10/1/2018
417From SITC: P424 NKTR-214, an engineered IL-2, selectivelydepletesintratumoral TMiljenko Zuanic-10/1/2018
416< the premise of it increasing TIL's and providing synergy with other mecMiljenko Zuanic-10/1/2018
415They have a slide presentation and report. I didn't read both just skimmingghmm-10/1/2018
414Devastating report: s3.amazonaws.comMiljenko Zuanic-10/1/2018
413Thanks!DewDiligence_on_SI-9/24/2018
412TIL, tumor infiltrating lymphocyte....and Nivo....Miljenko Zuanic19/24/2018
411Which tweet in that stream relates to IL-2?DewDiligence_on_SI-9/24/2018
410Finally something of substance on IL-2: twitter.comMiljenko Zuanic-9/24/2018
409Is DPP8/9 and FAP inhibitor (BXCL701) right target/compound? https://finance.yMiljenko Zuanic-9/24/2018
408Thanks. I would like to see what (IF any) did they trade in last few months. AlMiljenko Zuanic-7/4/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News